### 506859455 09/08/2021

### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6906275

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
AMGEN INC.	08/26/2021

#### **RECEIVING PARTY DATA**

Name:	AMGEN INC.
Street Address:	ONE AMGEN CENTER DRIVE
City:	THOUSAND OAKS
State/Country:	CALIFORNIA
Postal Code:	91320-1799
Name:	CYTOKINETICS, INC.
	OTTOKINE 1100, 1100.
Street Address:	280 EAST GRAND AVENUE
	· ·
Street Address:	280 EAST GRAND AVENUE

#### **PROPERTY NUMBERS Total: 3**

Property Type	Number
Patent Number:	10543215
Application Number:	16702989
Application Number:	62185306

#### **CORRESPONDENCE DATA**

506859455

**Fax Number:** (650)494-0792

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** (650) 813-5735

Email: ebowers@mofo.com
Correspondent Name: LISA N. SILVERMAN

Address Line 1: MORRISON & FOERSTER LLP

Address Line 2: 755 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304-1018

**ATTORNEY DOCKET NUMBER:** 49892-28016.00

NAME OF SUBMITTER: LISA N. SILVERMAN

PATENT REEL: 057417 FRAME: 0671

SIGNATURE:	/Lisa N. Silverman/
DATE SIGNED:	09/08/2021

## **Total Attachments: 2**

source=49892-28016.00 Joint Assignment\_Amgen and Cytokinetics\_fully executed by Fady Malik on 8.31.2021#page1.tif

source=49892-28016.00 Joint Assignment\_Amgen and Cytokinetics\_fully executed by Fady Malik on 8.31.2021#page2.tif

PATENT REEL: 057417 FRAME: 0672

#### JOINT ASSIGNMENT

This joint assignment agreement ("Assignment") is by and between AMGEN INC., having a place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799 ("AMGEN") and Cytokinetics, Inc., having a place of business at 280 East Grand Avenue, South San Francisco, California 94080 ("Cytokinetics"). This Assignment gives effect to the terms of Section 3.6 (Ownership of Research Patent Rights) of the Collaboration and Option Agreement between Amgen Inc. and Cytokinetics, Incorporated executed December 29, 2006, as amended (the "Agreement").

For good and valuable consideration as provided under the Agreement, the receipt and sufficiency of which are acknowledged, the parties agree as follows:

"Patent Rights" refers to any of the following, whether existing now or in the future anywhere in the world: (i) the patents and patent applications listed on Exhibit A hereto (ii) any issued patent, including without limitation inventor's certificates, utility model, substitutions, extensions, confirmations, reissues, re-examination, renewal or any like governmental grant for protection of the inventions described therein; and (iii) any pending application for any of the foregoing, including without limitation any continuation, divisional, substitution, additions, continuations-in-part, provisional and converted provisional applications.

AMGEN owns the Patent Rights from the assignment of rights from Inventors Robert Andrew Donald Scott and Scott Wasserman to AMGEN, and AMGEN hereby irrevocably assigns and transfers to AMGEN and Cytokinetics an equal and undivided right, title, and interest, both legal and equitable, including any right to institute actions and to recover damages for past, present and future infringement, throughout the world, in and to the Patent Rights so that AMGEN and Cytokinetics are joint owners of the Patent Rights, subject to, and in accordance with, the provisions of the Agreement.

This Assignment is binding on and inures to the benefit of the parties and their legal representatives, affiliates, successors and assigns.

The parties execute and deliver this Assignment by their respective signatories below.

Cytokinetics, Inc.

Name: Fady Malik MaPLD

Title: EVP RAD

Date: 4 31 Aug 2021

AMGEN INC.

Name: Stuart L. Watt

Title: Vice President, Law and Intellectual

ant L Watt

Property Officer

Date: ZG August 2021 at Thousand Oaks,

California USA

# Exhibit A

Country	Appl. No.	Filed	Patent No.
United States of America	15/578,305	11/30/2017	10,543,215
United States of America	16/702,989	12/4/2019	
PCT	PCT/US16/39198	6/24/2016	
Australia	2016282985	6/24/2016	
Canada	2988796	6/24/2016	
European Patent Office	16738288.6	6/24/2016	3313444
Japan	2017-566330	6/24/2016	6858716
Mexico	X/A/2017/016347	6/24/2016	MX 379899B
Switzerland	16738288.6	6/24/2016	3313444
Germany	16738288.6	6/24/2016	3313444
France	16738288.6	6/24/2016	3313444
United Kingdom	16738288.6	6/24/2016	3313444
United States of America	62/185,306	6/26/2015	